GovChime
Notice ID: b66a5e0061e440c7a64534a91b58e4beCombined Synopsis/Solicitation

Digital PCR Assay Panel Optimization, Design, & Construction Services

Archived on August 20, 2022. Original response deadline: . Full description on SAM.gov.

Overview

Response deadline
2:00 PM UTC−04:00
Posted
July 31, 2022
Notice type
Combined Synopsis/Solicitation
Set-aside
Total Small Business Set-Aside (FAR 19.5)
NAICS
541715: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Agency
Department of Health and Human ServicesCENTERS FOR DISEASE CONTROL AND PREVENTION

Notice details

Office
CDC OFFICE OF ACQUISITION SERVICES
Place of performance
Fort Collins, CO, 80524
Last updated
Dec 4, 2025

Identifiers

Solicitation number
75D301-22-Q-75423
Notice ID
b66a5e0061e440c7a64534a91b58e4be

Description

The Centers for Disease Control and Prevention (CDC) intends to award a fixed-price contract on a sole source basis to GT Molecular, LLC, Fort Collins, CO for Digital PCR assay panel optimization, design, and construction services for the Qiagen Qiacuity series and BioRad QX series digital PCR instruments. This is the only known Vendor who is able to construct and optimize a multi-pathogen, digital PCR-compatible assay panel from existing real time PCR assays in use by the Government and elsewhere, for use by the Government, its public health partners, and environmental laboratories to interrogate wastewater for multiple pathogen and AR targets in a standardized format. This service will involve constructing a multiplexed, multi- pathogen, digital PCR-based assay panel from approximately 30 existing PCR assays or molecular targets, as defined by the Government. To maximize compatibility with existing instrumentation at partner laboratories and to simplify data analysis and reporting to the Government, the panel will be developed for operation on the Bio-Rad QX series droplet digital PCR platform and the Qiagen Qiacuity series digital PCR platform, and will be limited to fluorescent dyes and corresponding instrument channels that are common to both instruments. This is the only known Vendor who is the only molecular assay development Vendor that is qualified and capable of accomplishing this service simultaneously for both digital PCR platforms. This Vendor is the only organization suited for these services because they currently employ both the Qiagen and the BioRad branded digital PCR platforms in-house, and thus, have direct, relevant experience in assay development and testing for both instruments. In addition, this Vendor is not restricted to a single brand molecular detection platform because they do not manufacture the PCR instruments, and have no interest in the success of one platform over another, which benefits the Government. The North American Industry Classification System Code (NAICS) for this requirement is 541715 with a size standard of 1,000 employees. This contract action is for supplies or services for which the Government intends to solicit and negotiate with only one source under the authority of FAR Part FAR 13.106 1 (b) and 10 U.S.C. 2304 (c) (1). Interested persons may identify their interest and capability to respond to the requirement or submit proposals. This Notice of Intent is not a request for competitive quotations; however, all quotations/responses received within six (6) calendar days of the issuance of this notice will be considered by the Government. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. Any quotation/response should be emailed to the Contract Specialist, Lee Catherine Kennedy, at vhg0@cdc.gov by 2:00pm ET, Friday, 5 October 2022.

Full description on SAM.gov

Award Overview

No prior contract identified

No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.

Contacts

Documents

No documents available.

Lifecycle

Solicitation:75D301-22-Q-75423
  1. Combined Synopsis
  1. 2×
    Combined SynopsisCurrentJul 30, 2022

    Digital PCR Assay Panel Optimization, Design, & Construction Services

    Notice b66a5e0061e440c7a64534a91b58e4be on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline
This is a SMALL BUSINESS SOURCES SOUGHT NOTICE. This is NOT a solicitation for proposals, proposal of abstracts or quotations. The purpose of this notice is to obtain information regarding: (1) the availability and capability of qualified small business sources; (2) whether they are small businesses (e.g., 8(a), Veteran-owned small businesses, service-disabled Veteran-owned small businesses, HUBZone small businesses, small disadvantaged businesses, and women-owned small businesses); (3) their size classification relative to the North American Industry Classification System (NAICS) code for the proposed acquisition; and (4) whether commercials sources and services are available in the marketplace. Your response to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. An organization that is not considered a small business under the applicable NAICS code 541715 should not submit a response to this notice. This notice is issued to help determine the appropriate acquisition method including small business socioeconomic set aside possibilities and to determine the availability of commercial or non-commercial companies technically capable of meeting the Government's potential requirement. It is not construed as a commitment by the Government to issue a solicitation or ultimately award a contract. Responses will not be considered as proposals or quotes. No award will be made as a result of this notice. The Government will NOT be responsible for any costs incurred by the respondents to this notice. This notice is strictly for research and information purposes only. Furthermore, it should be noted that any future solicitations that may be issued as a result of this notice, or in response to this requirement, may be issued using a different solicitation number from the one identified above. The National Institute on Drug Abuse (NIDA) Division of Therapeutics and Medical Consequences (DTMC) and National Institutes of Health (NIH) is seeking Capability Statements from Small Business organizations with the demonstrated capability of providing service to support NIDA DTMC with the synthesis and distribution of drugs of abuse and related compounds. BACKGROUND AND OBJECTIVES: The National Institute on Drug Abuse (NIDA) is seeking capability statements from small businesses with the capability to synthesize and distribute drugs of abuse and related compounds. The NIDA Drug Supply Program has played an important role in promoting and supporting the substance use research by providing a wide variety of authentic, pure, controlled and uncontrolled drugs and other chemical compounds (both unlabeled and labeled with deuterium, tritium, carbon -14, and iodine-125 isotopes) to the drug abuse research community for basic research. To continue to supply authentic and pure drugs and research chemicals, NIDA maintains the drug supply inventory, periodically check chemical purity and supply to research investigators according to the NIDA drug supply guidelines. Specifically, NIDA plans to continue to: (1) produce, acquire, synthesize and maintain several radio and deuterium labeled and unlabeled drugs of abuse and other chemical substances in its drug supply inventory and distribute them to research investigators upon approval; (2) analyze, test, establish, and maintain the purity of drugs of abuse, and other chemical compounds in the NIDA drug supply inventory and produce updated chemical data sheets; (3) to replenish existing drug supply inventory with depleted drugs and research compounds with the synthesis or acquisition of depleted drug/chemical substances routinely; (4) to identify, acquire, and update the drug supply inventory with newly discovered chemical compounds useful for drug abuse research; (5) to use, maintain, and update the NIDA drug supply data base, known as Drug Inventory Supply Control System (DISCS); and (6) accept and process request packages from researchers; (7) Provide secure storage for all compounds and safe shipment of approved drugs/compounds to research investigators. Capable vendors must demonstrate the capability to receive the current inventory of hundreds of DEA controlled and uncontrolled drugs, other chemical compounds including peptides (opioid and related neuropeptides) in several kilogram quantities for immediate storage. Many of these compounds will require refrigeration. Some substances are in solution form and therefore require appropriate and secure storage to meet DEA requirements. Chemical compounds to be synthesized shall include new drugs, drug metabolites and other compounds as directed by NIDA. Specific compounds may include but not be limited to unlabeled compounds as well as compounds labeled with tritium, 125I, 14C, and deuterium and 13C. Representative classes of compounds shall include cannabinoids, hallucinogens, narcotics and antagonists, stimulants, depressants, peptides (opioid and related neuropeptides). All chemical compounds must be stored under optimum shelf‑life conditions and their purity maintained at not less than 95%. Re-purification must be carried out if chemical or radiochemical deterioration occurs. MANDATORY REQUIREMENTS: To handle controlled substances under the Controlled Substances Act of 1970, it is mandatory that the successful capable vendors possess a DEA Research Registration for Schedules II to V and demonstrate the capability to obtain a DEA registration for Schedule I controlled substances. INSTRUCTIONS: Based on preliminary market research, the Government has determined that the requirements described herein do not meet the definition of a commercial product or commercial service as defined in RFO 2.101, and therefore, RFO Part 12 procedures are not applicable to this requirement. However, if a capable vendor believes that these services or products qualify as commercial under FAR 2.101, the vendor may submit a written justification for the Contracting Officer's consideration. Such submissions must be provided to the Contracting Officer no later than November 20, 2026 at 1:00 PM EST. Respondents must provide clear and convincing documentation of their capability and experience with providing the personnel and services as specified in the tasks above. Also, information must be provided in sufficient details of the respondents’ (a) staff expertise, including their availability, experience, formal and other training; (b) current capability to perform the work; (c) prior completed projects of similar nature; (d) corporate experience and other management capability; and (e) examples of prior completed Government contracts, references, and other related information. Each capability statement must include the respondent’s UEI number, organization name, and address. Each response should include the technical and administrative points of contact with, names, titles, addresses, telephone numbers, and e-mail addresses. The capability statement should clearly identify the size and type of business (e.g., 8(a), HubZone, Non-Profit, Other Than Small Business, etc.), pursuant to the applicable NAICS code and any other information that may be helpful in developing or finalizing the acquisition requirements. One (1) copy of the response is required and must be in Microsoft Word or Adobe PDF format using 11-point or 12-point font, 8-1/2” x 11” paper size, with 1” top, bottom, left and right margins, and with single or double spacing. The information submitted must be in an outline format that addresses each of the elements of the project requirement and in the capability statement paragraphs stated herein. A cover page and an executive summary may be included but is not required. The response is limited to ten (10) pages. The 10-page limit does not include the cover page, executive summary, resumes, or references, if requested. Any business concerns that believe they possess the capability necessary to successfully undertake the work described above must SUBMIT CAPABILITY STATEMENTS ELECTRONICALLY to the Contract Specialist, Shaun Rostad at Shaun.Rostad@nih.gov, NO LATER THAN 1:00 p.m. EST on November 20, 2026. The Subject line for the submission should include this Sources Sought Number, SAM.gov Unique Entity Identifier (UEI) and organization name. NIDA will not accept paper or faxed capability statements. THIS NOTICE IS NOT A REQUEST FOR PROPOSALS. This notice is for information and planning purposes only and does not commit the Government to any contractual agreement. This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization’s qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a pre-solicitation synopsis and solicitation may be published in SAM.gov. However, responses to this notice will not be considered adequate responses to a solicitation. CONFIDENTIALITY. No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s).
-Market Research11/20/2026
The Advanced Research Projects Agency for Health (ARPA-H) is soliciting proposals from small business concerns (SBCs) that possess the research and development (R&D) expertise to conduct innovative research that will contribute toward ARPA-H mission needs, Small Business Innovation Research (SBIR), and Small Business Technology Transfer (STTR) program objectives. Please see the cover page of the attachment "SBIR_STTR_BAA_FY26" for applicable Stage 1 and Stage 2 deadlines for each open topic. Please see the Attachment H "ARPA-H_SBP_Government_Answered_Questions" for responses to the Q&A period. The purposes of the SBIR and STTR programs are to: (a) stimulate technological innovation; (b) strengthen the role of small business in meeting Federal research/research & development (R/R&D) needs; (c) foster and encourage participation by socially and economically disadvantaged small business concerns and women-owned business concerns; and (d) increase private sector commercialization of innovations derived from Federal R/R&D, thereby increasing competition, productivity and economic growth. For purposes of the SBIR and STTR programs, a small business concern is any business concern that, on the date of award, (1) is organized for profit, with a place of business located in the United States, which operates primarily within the United States or which makes a significant contribution to the United States economy through payment of taxes or use of American products, materials or labor; (2) is in the legal form of an individual proprietorship, partnership, limited liability company, corporation, joint venture, association, trust or cooperative, except that where the form is a joint venture, there must be less than 50 percent participation by foreign business entities in the joint venture; (3) more than 50% directly owned and controlled by one or more individuals (who are citizens or permanent resident aliens of the United States), other business concerns (each of which is more than 50% directly owned and controlled by individuals who are citizens or permanent resident aliens of the United States), or any combination of these; OR more than 50% owned by multiple venture capital operating companies, hedge funds, private equity firms, or any combination of these. No single venture capital operating company, hedge fund, or private equity firm may own more than 50% of the concern; AND, (4) has, including its affiliates, no more than 500 employees. Note: This size standard is established by law for the SBIR program, regardless of the NAICS Code assigned. See 13 C.F.R. § 121.702. AMENDMENT 01 - July 8, 2026: Amendment 01 of this solicitation extends the deadline for Stage 1 Solution Summaries from July 10, 2026 to July 17, 2026. This amendment answers conforming questions that were submitted prior to the Q&A deadline via Attachment H. This amendment adds/revises the following soliciation sections: Add change log, revise sections 2.3, 3.1, 3.2, 4.2, 4.3, 4.4, 5.0, 5.4, add section 5.5, revise section 8, topic 6, and topic 7. AMENDMENT 02 - August 17, 2026: Amendment 02 of this solicitation publishes the Stage 2 submission deadline for Topics 01, 02, 03, 04, 06, and 07. This amendment revises language in the following sections: cover page, 2.2, 2.3, 2.4, 2.6, 2.8, and 8. Amendment 02 corresponds with Stage 1 encourage/discourage letter distribution for topics 01, 02, 03, 04, 06, and 07. Please check your email inbox for your Stage 1 encourage/discourage letters on or around August 17, 2026. Topic 05 Stage 1 letters and Stage 2 submission deadline will be distributed at a later date. AMENDMENT 03 - September 1, 2026: Amendment 03 of this solicitation publishes the Stage 2 submission deadline for Topic 05. This amendment revises language in the following sections: cover page and 8. Amendment 03 corresponds with Stage 1 encourage/discourage letter distribution for topic 05. Please check your email inbox for your Stage 1 encourage/discourage letters on or around September 1, 2026. Amendment 03 updates Attachment B Cost Proposal Spreadsheet Template. AMENDMENT 04 - September 10 2026: Amendment 04 of this solicitation revises the Stage 2 submission deadline for Topics 01, 02, 03, 04, 06, and 07. This amendment revises language in the following section: cover page and 8. This amendment updates Attachment B Cost Proposal Spreadsheet Template. AMENDMENT 05 - September 11 2026: Amendment 05 of this solicitation revises the Stage 2 submission deadline for Topics 01, 02, 03, 04, 06, and 07. This amendment revises language in the following section: cover page and 8. This amendment updates Attachment B Cost Proposal Spreadsheet Template. This amendment also unprotects Attachment B Cost Proposal Spreadsheet and updates the instructions sheet. THE FOLLOWING ARE THE CURRENTLY OPEN RESEARCH TOPICS. PLEASE SEE SECTION 8 OF THE BAA FOR FURTHER INFORMATION ARPA-H 01 - Development of an annual test to inform women about their future fertility - The purpose of this topic is to discover new biomarkers that provide women with actionable data for fertility planning. Results from this work will help inform the program manager regarding the feasibility of future programs focused on enhancing natural fertility before the need of IVF and guiding the development of women’s health monitoring and improvement tools. This work will develop a diagnostic test that can assess fertility status and generate an estimated timeline for the onset of infertility. This topic seeks to develop a test that is affordable, suitable for at least annual use, and provides user-friendly results for patients and care teams to support childbearing decisions. ARPA-H 02 - Versatile Bioadhesives - The purpose of this topic is to develop next-generation bioadhesive platforms that can safely and reliably seal, bond, and repair a wide range of tissues in challenging clinical conditions, including wet, bloody, and mechanically dynamic environments. These platforms may also be designed to deliver biologics or small molecules as part of treatment. The goal is to create bioadhesives with key performance attributes such as strong tissue adhesion, controlled degradation, reversibility, biocompatibility, and broad compatibility across multiple tissues and organs. If successful, this topic could enable widely deployable solutions for hemostasis, leak prevention, tissue repair, and device fixation, ultimately helping reduce complications and improve patient outcomes across many care settings ARPA-H 03 - Universal Platform for Living Adaptive Toxin-removal (UNI-PLAT) - The purpose of this topic area is to catalyze the development of a universal, “plug-and-play” synthetic biology platform that enables next-generation microbial chassis capable of performing a broad array of programmable functions. While this solicitation primarily uses toxin removal as a proof-of-concept in relation to chronic disease management, the platform is intended to be adaptable to a range of challenges across industries such as environmental remediation, biomanufacturing, agriculture, holistic medicine, and therapeutic discovery. The broader goal is to create a stable, reliable, and easily reprogrammable microbial platform that demonstrates potential for cross-sector impact beyond the initial use case. ARPA-H 04 - Breaking Ground: The First Curative, Durable, Non-Surgical Therapy for Endometriosis – The purpose of this topic aims to develop treatments for endometriosis that are non-surgical. Proposers are expected to develop novel, non-surgical therapies to decrease the size or deactivate endometrial implants, to decrease inflammation cause by implants, and / or prevent growth or regrowth of the lesions. Broadly, this should be a novel, non-surgical, curative treatment for endometriosis. ARPA-H 05 - ARPA-H Lineage Topic - The purpose of this topic supports the advancement, commercialization, and translation of technologies that originated from ARPA-H funded efforts. It is intended to help small businesses and startups develop viable products based on these technologies. ARPA-H’s goal is to give small businesses an off-ramp to finish developing their technology/product, explore secondary or interim applications of the technology, and time to achieve self-sufficiency. ARPA-H 06 - Rapid Comprehensive Diagnostic Test for Multi-System Autoimmune Disease -The purpose of this topic is to spur the development of novel, rapid diagnostic assays for multi-system autoimmune disease, which represents an unmet healthcare need. Moreover, in its ideal embodiment this diagnostic test might allow typical primary care physicians to diagnose and predict tissue-specific autoimmune disease manifestations, thereby streamlining referral of the patient to a specialist. This goal is made more feasible by recent technological developments including the ability to detect tissue-specific signatures of immune-mediated stress by assessing circulating cells and/or tissue-specific molecular products. ARPA-H 07 - Virtual Human Brain for the Development of Neurosurgical Robotics - The purpose of this topic aims to take a first step toward AI-assisted intracranial microsurgery by creating a high-resolution, physically and anatomically accurate virtual human brain.
-Pre-Solicitation10/01/2026
**Please see Amendment 4 dated 11/03/2026.** **Please see Amendment 3 dated 11/02/2026.** **Please see Amendment 2 dated 10/30/2026.** **Please see Amendment 1 dated 10/15/2026.** NLR seeks to engage leading technical subject matter experts (SMEs) to help buildings industry stakeholders scale up and meet demand for lower-cost, high-quality buildings. SMEs will support DOE’s Building America program, both its just-launched new construction support program and existing support programs for building envelope retrofits. The new construction support program will provide technical assistance to help partners erect high-quality buildings faster and at lower cost, ultimately delivering savings to everyday Americans. NLR seeks leading subject matter experts (SMEs) in research, field validation, analysis, dissemination, and technical support efforts to help builders, manufacturers, contractors, and other industry stakeholders scale up and meet demand. This work will focus on factory optimization, product design and materials innovation, and digital tools and modeling. For envelope retrofits, this work will help reduce first costs and lower utility bills in existing homes by focusing on technical topics including, but not limited to, addressing moisture, humidity, and infiltration through envelope upgrades and whole-home solutions. Across both areas, SMEs will also conduct modeling and analysis, data collection, industry analysis, and market scaling support. This work will include knowledge transfer to provide actionable guidance and information to industry stakeholders. For over 30 years, DOE’s Building America Program has been a source of innovations and best practices needed to deliver affordable and efficient homes. NLR supports DOE’s Building America Program through scientific leadership and building science expertise to ensure high-quality, impactful results from Building America’s research efforts.
-Solicitation11/16/2026
18 Mar 2026 Updated: Space Domain Awareness (SDA) Commercial Solutions Opening (CSO) Phase I. The initial evaluation for phase I has been completed. We received a significant number of responses, and our team has given each submission the careful consideration it deserves. We will now begin the process of formally notifying all participants. This will be conducted in stages, starting with the offerors who were identified as "Not Selectable", followed by those deemed "Selectable", and concluding with the offeror(s) "Recommended" for selection. We appreciate your patience as we proceed with these Phase I final steps, and thank you for your continued patience as the notification process is executed. All participants will receive a formal notification regarding the status of their submission. 25 Feb 2026 Updated: Space Domain Awareness (SDA) Commercial Solutions Opening (CSO) Phase I. We would like to inform you that the evaluation of white papers is currently ongoing. Due to the overwhelming response to this solicitation, our team is carefully reviewing all submissions to ensure a thorough and fair assessment are in alignment with the program's objectives and requirements. We appreciate the effort and thoughtfulness demonstrated in your submission and your interest in supporting this initiative. Once the evaluation process is complete, we will provide further updates regarding next steps and any additional requirements. Should you have any questions or need clarification in the meantime, please feel free to reach out to us directly. Thank you for your continued engagement and support of the SDA CSO program. Amendment 03_AOI 01 AOI-2025_01 - Amendment 2: CO Q&A Document Updated Amendment 2 has been posted to update the Question and Answer (Q&A) document for this acquisition. Please feel free to reach out with any further questions. Amendment 02_AOI 01 AOI-2025_01 - Amendment 1: CO Contact Updated and Q&A Amendment 1 has been posted to update the Contracting Officer contact information for this acquisition. A list of questions and answers for AOI-2025_01 are also attached. Please feel free to reach out with any further questions. Amendment 01 _ AOI 01 AOI-2025_01 - Solicitation Request: CFC SAIO/PKO is soliciting white papers on the effort(s) identifed as Area(s) of Interest (AOIs) to this solicitation. Type of Contract: This is a Fixed-Price type contract IAW FAR Part 12 and Part 35. Limitation: This acquisition is set aside for small business. Anticipated Award: Government reserves the right to award all, some, or none of the proposed solutions. Classified Information: Offerors are encouraged to submit unclassified White Papers to simplify and expedite reviews and response by the Government. Description The United States Space Force (USSF), through the Space Acquisition & Integration Office (SAIO), is issuing this Commercial Solutions Opening (CSO)to solicit innovative commercial solutions that enhance Space Domain Awareness (SDA)capabilities. This CSO is authorized under DFARS 212.70and is designed to identify and acquire innovative technologies, products, and services that support the USSF's warfighting missions. The CSO provides a flexible, enterprise-wide acquisition mechanism to address SDA mission challenges through advanced software engineering, data analytics, and other innovative approaches. Submissions will be evaluated under a multi-phase process to ensure alignment with mission needs and operational priorities. Scope of the CSO The CSO seeks solutions that address the following Space Domain Awareness (SDA)mission challenges: Detecting, characterizing, and predicting activities in the space domain. Enhancing the accuracy and timeliness of SDA data. Supporting emerging SDA missions through innovative technologies. Specific Areas of Interest (AOIs) will be issued under this CSO to define technical focus areas, submission requirements, and evaluation criteria. Each AOI will be posted as a standalone solicitation module under this CSO. Submission Process The CSO employs a three-phase submission process: Phase I – White Paper and PowerPoint Briefing Offerors must submit a PowerPoint briefing (including a Quad Chart) and a White Paper summarizing their proposed solution. Submissions must align with the specific AOI requirements. Phase II – Pitch Session (Optional) Selected Offerors may be invited to present their proposed solution in greater depth during a virtual or in-person pitch session. Phase III – Full Proposal Offerors invited to Phase III must submit a complete proposal package, including a Technical Proposal, Performance Work Statement (PWS), and Price Proposal. The Government reserves the right to proceed directly from Phase I to Phase III. Key Information Security Requirements: Phase I submissions must be unclassified. Subsequent phases may require higher classification levels, as specified in the AOI and any draft or final DD Form 254. Foreign Participation: Restricted to U.S. entities due to export control and national security considerations. Cybersecurity Compliance: Offerors must comply with NIST SP 800-171 and CMMC 2.0 requirements. How to Respond Interested Offerors must monitor SAM.gov for AOI-specific postings under this CSO. Each AOI will include detailed submission instructions, evaluation criteria, and deadlines. Submissions must comply with the formats and requirements outlined in the CSO and the applicable AOI. For general inquiries, contact the SAIO CSO Contracting Officer at SAIO.SDA.CSO@spaceforce.mil. Use the subject line: "SDA CSO – General Question(s)". Disclaimer This CSO does not obligate the Government to award a contract, nor does it commit the Government to pay for any costs incurred in the preparation and submission of responses. The Government reserves the right to fund all, some, or none of the proposals received under this CSO.
-Combined Synopsis01/23/2030
Amendment 0011: Please see the attached OTTI CSO FA2553-25-S-C001 Amend 0011. This amendment supersedes all versions of the OTTI CSO. Annual Notice: In accordance with DFARS 212.7004(b), this posting serves as an annual notice of the OTTI CSO FA2553-25-S-C001 publishing. Amendment 0010: Please see the attached OTTI CSO FA2553-25-S-C001 Amend 0010. This amendment supersedes all versions of the OTTI CSO. AOI 05 Q&As: Please see the attached OTTI CSO AOI 05 Questions_Answers document for AOI 05: Continuous Fitness Assessment (CFA). The Phase I submission accepted until date for AOI 05 has been extended from 7 November 2025 to 5 December 2025. Amendment 0009: Please see the attached OTTI CSO FA2553-25-S-C001 Amend 0009. This amendment supersedes all versions of the OTTI CSO. AOI 05: Continuous Fitness Assessment (CFA) is currently pending Government updates. Additional information will be released to industry via an amendment to this solicitation. The Phase I submission accepted until date for AOI 05 has been extended from 8 October 2025 to 7 November 2025. Amendment 0008: Please see the attached OTTI CSO FA2553-25-S-C001 Amend 0008. This amendment supersedes all versions of the OTTI CSO. Amendment 0007: Please see the attached OTTI CSO FA2553-25-S-C001 Amend 0007. This amendment supersedes all versions of the OTTI CSO. Amendment 0006: Please see the attached OTTI CSO FA2553-25-S-C001 Amend 0006. This amendment supersedes all versions of the OTTI CSO. AOI 04 Q&As Rev 01: Please see the attached (CUI) OTTI CSO AOI 04 - Questions_Answers_Rev 01 document for AOI 04: Multirole Satellite Frequency In-field Test Suite (MSFITS). This updated document provides additional questions and answers (AOI 04 - Q16 through AOI 04 - Q30). Amendment 0005: Please see the attached OTTI CSO FA2553-25-S-C001 Amend 0005. This amendment supersedes all versions of the OTTI CSO. AOI 04 Q&As: Please see the attached (CUI) OTTI CSO AOI 04 Questions_Answers document for AOI 04: Multirole Satellite Frequency In-field Test Suite (MSFITS). Amendment 0004: Please see the attached OTTI CSO FA2553-25-S-C001 Amend 0004. This amendment supersedes all versions of the OTTI CSO. Amendment 0003: Please see the attached OTTI CSO FA2553-25-S-C001 Amend 0003. This amendment supersedes all versions of the OTTI CSO. AOI 02 Q&As Rev 01: Please see the attached OTTI CSO AOI 02 Questions_Answers_Rev01 document for AOI 02: National Space Test and Training Complex (NSTTC) Range Control System Enhancements. This updated document provides an additional question and answer (AOI 02 - Q10). AOI 03 Q&As: Please see the attached OTTI CSO AOI 03 Questions_Answers document for AOI 03: Distributed Synthetic Training Environment Evolution & Prototyping. AOI 02 Q&As: Please see the attached OTTI CSO AOI 02 Questions_Answers document for AOI 02: National Space Test and Training Complex (NSTTC) Range Control System Enhancements. Amendment 0002: Please see the attached OTTI CSO FA2553-25-S-C001 Amend 0002. This amendment supersedes all versions of the OTTI CSO. Amendment 0001: Please see the attached OTTI CSO FA2553-25-S-C001 Amend 0001. This amendment supersedes all versions of the OTTI CSO. The United States Space Force (USSF) Operational Test and Training Infrastructure (OTTI) is seeking innovative capabilities, solutions, and technological advancements. The OTTI Commercial Solutions Opening (CSO) is being issued in accordance with Defense Federal Acquisition Regulation Supplement (DFARS) 212.70. OTTI is requesting submissions from interested Offerors in response to the specific Areas of Interest (AOI) identified in the OTTI CSO. Please see the attached OTTI CSO FA2553-25-S-C001 for all information.
-Solicitation12/08/2029

Additional Details

Solicitation Number

75D301-22-Q-75423

Archive Date

Aug 20, 2022

Office Address

ATLANTA, GA, 30333